The findings from the IMpower010 study (24) indicate that, in comparison to the placebo group, postoperative chemotherapy followed by one year of adjuvant immunotherapy significantly improves DFS in R0 stage II–IIIA NSCLC patients with PD-L1 expression on 1% or more of tumor cells (hazard ratio [HR], 0.66). The gene discussed is CD274; the disease is non-small cell lung carcinoma.